Vanda Pharmaceuticals Announces The U.S. Patent And Trademark Office Issued A Notice Of Allowance For PONVORY #17/962,968, Covering Methods For Reducing Clinical Management Events Before Or During The Treatment Of MS And Methods For Reinitiating Treatment After Missed Doses
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals Inc. (VNDA) announced that the U.S. Patent and Trademark Office has issued a notice of allowance for a patent application related to PONVORY®, a treatment for multiple sclerosis. The patent covers methods for reducing clinical management events and reinitiating treatment after missed doses, with an anticipated expiration date of October 10, 2042. Vanda plans to list the patent in the FDA's Orange Book. Vanda acquired the rights to PONVORY® in the U.S. and Canada from Actelion Pharmaceuticals Ltd., a subsidiary of Johnson & Johnson.
January 26, 2024 | 3:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vanda Pharmaceuticals received a notice of allowance for a patent on PONVORY®, which could strengthen its market position in MS treatments and potentially enhance its revenue prospects.
The notice of allowance for the PONVORY® patent is likely to have a positive impact on VNDA's stock in the short term as it secures the company's intellectual property rights and may provide a competitive edge in the MS treatment market. The extended patent life until 2042 also suggests a longer period of market exclusivity, which can lead to increased sales and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100